These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26453388)

  • 21. Levodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease.
    Morales-Briceño H; Mahant N; Duma S; Martin A; Griffith J; Tsui D; Fung VS
    Parkinsonism Relat Disord; 2019 Aug; 65():282-283. PubMed ID: 31221564
    [No Abstract]   [Full Text] [Related]  

  • 22. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
    Steiger MJ; Quinn NP; Toone B; Marsden CD
    Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932
    [No Abstract]   [Full Text] [Related]  

  • 24. Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.
    Ahlskog JE
    Mayo Clin Proc; 2014 Jul; 89(7):997-1003. PubMed ID: 24996235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose-dependent memory impairment in Parkinson's disease.
    Huber SJ; Shulman HG; Paulson GW; Shuttleworth EC
    Neurology; 1989 Mar; 39(3):438-40. PubMed ID: 2927659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease.
    Nyholm D; Klangemo K; Johansson A
    Eur J Neurol; 2012 Aug; 19(8):1079-85. PubMed ID: 22360705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lees' syndrome: a case series.
    Becker N; Munhoz RP; Teive HA
    Arq Neuropsiquiatr; 2011 Oct; 69(5):756-9. PubMed ID: 22042176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia.
    Bendi VS; Shou J; Joy S; Torres-Russotto D
    Parkinsonism Relat Disord; 2018 May; 50():126-127. PubMed ID: 29467094
    [No Abstract]   [Full Text] [Related]  

  • 29. Dopamine dysregulation syndrome induced by proxy.
    Reis Carneiro D; Sousa M; Morgadinho A; Januário C
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31101748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease patients cannot get their dopamine replacement: the 8-Sinemet limit.
    Okun MS
    Mov Disord; 2012 Mar; 27(3):461-2. PubMed ID: 22162080
    [No Abstract]   [Full Text] [Related]  

  • 31. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 32. Levodopa/carbidopa intestinal gel for pain related to levodopa-induced motor complications in Parkinson's disease.
    Rinaldi D; De Carolis L; Ceriello F; Bianchini E; Pontieri FE
    Neurol Sci; 2022 Jul; 43(7):4571-4572. PubMed ID: 35411502
    [No Abstract]   [Full Text] [Related]  

  • 33. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
    Melgari JM; Salomone G; di Biase L; Marano M; Scrascia F; Di Lazzaro V
    Parkinsonism Relat Disord; 2015 Mar; 21(3):327-8. PubMed ID: 25595317
    [No Abstract]   [Full Text] [Related]  

  • 34. [Modeling of schizophrenia with Levodopa + Carbidopa].
    Kucher EO; Egorov AIu; Chernikova NA; Filatova EV
    Zh Evol Biokhim Fiziol; 2013; 49(5):352-6. PubMed ID: 25434191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
    Iyer SS; Morgan JC; Sethi KD
    Neurology; 2005 Nov; 65(9):1507. PubMed ID: 16275853
    [No Abstract]   [Full Text] [Related]  

  • 36. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.
    Klostermann F; Jugel C; Bömelburg M; Marzinzik F; Ebersbach G; Müller T
    Mov Disord; 2012 Nov; 27(13):1704-5. PubMed ID: 23192929
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 38. Sinemet CR for Parkinson's disease.
    Med Lett Drugs Ther; 1991 Oct; 33(854):92-3. PubMed ID: 1895993
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa].
    Linazaroso G; van Blercom N; Lasa A
    Neurologia; 2004 Apr; 19(3):117-27. PubMed ID: 15088161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible serotonin syndrome with carbidopa-levodopa and linezolid.
    Pettit NN; Alonso V; Wojcik E; Anyanwu EC; Ebara L; Benoit JL
    J Clin Pharm Ther; 2016 Feb; 41(1):101-3. PubMed ID: 26813986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.